无创产前检测：迈向下一个十年
收稿日期: 2023-12-12
网络出版日期: 2024-01-05
基金资助
上海交通大学医工交叉重点项目(YG2023ZD26)
Noninvasive prenatal testing: moving into the next decade
Received date: 2023-12-12
Online published: 2024-01-05
无创产前基因检测（NIPT）是过去10余年来产前筛查领域的重大突破，是围产医学领域的引领技术。通过低深度全基因组测序分析孕妇外周血胎儿游离DNA（cffDNA），实现了高效的唐氏综合征产前筛查，同时可扩展应用于其他染色体非整倍体、拷贝数变异等常见胎儿基因组问题的筛查，实现胎儿疾病的早期无创检测。但是，NIPT依然需要更多循证医学证据支持，以迈向更为广阔的应用空间。文章从NIPT适应证选择、NIPT异常结果分析、NIPT结果报道与解读中的伦理学问题、NIPT在胎儿基因变异筛查中的应用以及非cffDNA来源NIPT技术开发等角度，探讨了NIPT目前面临的问题与未来的发展趋势。
王彦林 . 无创产前检测：迈向下一个十年[J]. 临床儿科杂志, 2024 , 42(1) : 15 -19 . DOI: 10.12372/jcp.2024.23e1192
Noninvasive prenatal testing (NIPT) was one of the most inspiring breakthroughs in prenatal diagnosis over the last ten years, leading the technology advancements in perinatal medicine. Through the analysis of maternal peripheral blood cffDNA by low-coverage whole-genome sequencing, NIPT has realized the efficient prenatal screening of Down syndrome, and it can be extended to screen other genomic disorders such as aneuploidies and copy number variations, realizing the early non-invasive diagnosis of fetal diseases. Despite the outstanding outcomes, NIPT still needs more evidence-based medical support to expand its clinical application in the future. This article explores the current challenges and future development trends of NIPT from the perspectives of identifying indications, analyzing abnormal results, ethical issues in reporting and interpreting results, the role of NIPT in fetal Mendelian disorder screening, and the development of non cffDNA based NIPT technology.
| [1] | 孙锟. 宫内儿科学的理念与实践[J]. 临床儿科杂志, 2023, 41(1): 1-5. |
| [2] | Dungan JS, Klugman S, Darilek S, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)[J]. Genet Med, 2023, 25(8): 100874. |
| [3] | Yeaton-Massey A, Sparks TN, Norton ME, et al. Twin chorionicity and zygosity both vary with maternal age[J]. Prenat Diagn, 2021, 41(9): 1074-1079. |
| [4] | Batsry L, Yinon Y. The vanishing twin: diagnosis and implications[J]. Best Pract Res Clin Obstet Gynaecol, 2022, 84: 66-75. |
| [5] | Wang Y, Qiu X, Chen S, et al. Noninvasive evaluation of fetal zygosity in twin pregnancies involving a binary analysis of single-nucleotide polymorphisms[J]. J Mol Diagn, 2023, 25(9): 682-691. |
| [6] | Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies[J]. JAMA, 2015, 314:162-169. |
| [7] | Ji X, Li J, Huang Y, et al. Identifying occult maternal malignancies from 1.93 million pregnant women undergoing noninvasive prenatal screening tests[J]. Genet Med, 2019, 21(10): 2293-2302. |
| [8] | Dondorp W, de Wert G, Bombard Y, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening[J]. Eur J Hum Genet, 2015, 23(11): 1438-1450. |
| [9] | Gravholt CH, Chang S, Wallentin M, et al. Klinefelter syndrome: integrating genetics, neuropsychology, and endocrinology[J]. Endocr Rev, 2018, 39(4): 389-423. |
| [10] | D'Aversa E, Breveglieri G, Pellegatti P, et al. Non-invasive fetal sex diagnosis in plasma of early weeks pregnants using droplet digital PCR[J]. Mol Med, 2018, 24(1): 14. |
| [11] | Hill M, Compton C, Karunaratna M, et al. Client views and attitudes to non-invasive prenatal diagnosis for sickle cell disease, thalassaemia and cystic fibrosis[J]. J Genet Couns, 2014, 23(6): 1012-1021. |
| [12] | Lo YM, Bowell PJ, Selinger M, et al. Prenatal deter-mination of fetal RhD status by analysis of peripheral blood of rhesus negative mothers[J]. Lancet, 1993, 341(8853): 1147-1148. |
| [13] | Clausen FB, Damkj?r MB, Dziegiel MH. Noninvasive fetal RhD genotyping[J]. Transfus Apher Sci, 2014, 50(2): 154-162. |
| [14] | Clausen FB, Rieneck K, Krog GR, et al. Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis[J]. Methods Mol Biol, 2019, 1885: 347-359. |
| [15] | Chitty LS, Griffin DR, Meaney C, et al. New aids for the non-invasive prenatal diagnosis of achondroplasia: dysmorphic features, charts of fetal size and molecular confirmation using cell-free fetal DNA in maternal plasma[J]. Ultrasound Obstet Gynecol, 2011, 37(3): 283-289. |
| [16] | Chitty LS, Mason S, Barrett AN, et al. Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach[J]. Prenat Diagn, 2015, 35(7): 656-662. |
| [17] | Mohan P, Lemoine J, Trotter C, et al. Clinical experience with non-invasive prenatal screening for single-gene disorders[J]. Ultrasound Obstet Gynecol, 2022, 59(1): 33-39. |
| [18] | Xu C, Li J, Chen S, et al. Genetic deconvolution of fetal and maternal cell-free DNA in maternal plasma enables next-generation non-invasive prenatal screening[J]. Cell Discov, 2022, 8(1): 109. |
| [19] | Brand H, Whelan CW, Duyzend M, et al. High-resolution and noninvasive fetal exome screening[J]. N Engl J Med, 2023, 389(21): 2014-2016. |
| [20] | Miceikait? I, Hao Q, Brasch-Andersen C, et al. Com-prehensive noninvasive fetal screening by deep trioexome sequencing[J]. N Engl J Med, 2023, 389(21): 2017-2019. |
| [21] | Brand H, Whelan CW, Duyzend M, et al. High-resolution and noninvasive fetal exome screening[J]. N Engl J Med, 2023, 389(21): 2014-2016. |
/
| 〈 |
|
〉 |
沪公网安备 31011002000392号
